Elke Pfaff
Research Subjects
Elke Pfaff has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- David T.W. Jones
Hopp Children's Cancer Center Heidelberg (KiTZ)
12 shared publications - Ingrid Øra
Department of Clinical Sciences, Lund University, Lund, Sweden
11 shared publications - Stefan M. Pfister
Hopp Children's Cancer Center Heidelberg (KiTZ)
11 shared publications - Adam Resnick
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
10 shared publications - Birgit Geoerger
Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
10 shared publications - Caroline Hutter
St Anna Kinderspital, Department of Pediatrics, Medical University of Vienna, Vienna, Austria
10 shared publications
Latest Publications
- Open Access
- 12 March 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (7) , 1849-1863
Germline analysis of an international cohort of pediatric diffuse midline glioma patients
Background: Factors that drive the development of diffuse midline gliomas (DMG) are unknown. Our study aimed to determine the prevalence of pathogenic/likely pathogenic (P/LP) germline variants in pediatric patients with DMG. Methods: We assembled an international cohort of 252 pediatric patients with DMG, including diffuse intrinsic pontine glioma (n = 153), with germline whole genome or whole exome sequencing. Results: We identified P/LP germline variants in cancer predisposition genes in 7.5% (19/252) of patients. Tumor profiles differed, with the absence of somatic drivers in the PI3K/mTOR pathway in patients with germline P/LP variants versus those without (P = .023). P/LP germline variants were recurrent in homologous recombination (n = 9; BRCA1, BRCA2, PALB2) and Fanconi anemia genes (n = 4). Somatic findings established that the germline variants definitively contributed to tumorigenesis in at least 1% of cases. One patient with recurrent DMG and pathogenic germline variants (BRCA2, FANCE) showed a near-complete radiological response to PARP and immune checkpoint inhibition. Conclusions: Our study determined the prevalence of pathogenic germline variants in pediatric DMG and suggests a role in tumorigenesis for a subset of patients.
- 12 March 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (7) , 1849-1863
Open AccessGermline analysis of an international cohort of pediatric diffuse midline glioma patients
Background: Factors that drive the development of diffuse midline gliomas (DMG) are unknown. Our study aimed to determine the prevalence of pathogenic/likely pathogenic (P/LP) germline variants in pediatric patients with DMG. Methods: We assembled an international cohort of 252 pediatric patients with DMG, including diffuse intrinsic pontine glioma (n = 153), with germline whole genome or whole exome sequencing. Results: We identified P/LP germline variants in cancer predisposition genes in 7.5% (19/252) of patients. Tumor profiles differed, with the absence of somatic drivers in the PI3K/mTOR pathway in patients with germline P/LP variants versus those without (P = .023). P/LP germline variants were recurrent in homologous recombination (n = 9; BRCA1, BRCA2, PALB2) and Fanconi anemia genes (n = 4). Somatic findings established that the germline variants definitively contributed to tumorigenesis in at least 1% of cases. One patient with recurrent DMG and pathogenic germline variants (BRCA2, FANCE) showed a near-complete radiological response to PARP and immune checkpoint inhibition. Conclusions: Our study determined the prevalence of pathogenic germline variants in pediatric DMG and suggests a role in tumorigenesis for a subset of patients.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S3. Survival outcome.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S3. Survival outcome.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.
- Open Access
- 3 December 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (3) , 561-572
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.
- 3 December 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (3) , 561-572
Open AccessClinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.